Pertussis - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for pertussis including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, and target.

Overview of the drug development for pertussis

Pertussis is a highly contagious respiratory disease and is also known as whooping cough. The Bordetella pertussis bacterium is the causing agent of pertussis. When infected by pertussis, patients suffer from uncontrollable, violent coughing, which often makes it difficult to breathe. After coughing, someone with pertussis often needs to take deep breaths, which results in a whooping sound. People of all ages can be affected by pertussis, but it can be very serious, even deadly, for infants aged less than 1 year. People with pertussis usually spread the disease to another person by coughing or sneezing, or when spending a lot of time near one another where they share the breathing space. Many babies with pertussis are infected by older siblings, parents, or caregivers, who are unaware that they have this disease. According to the CDC, in 2015, the World Health Organization reported 142,512 pertussis cases globally and estimated that there were 89,000 deaths. Since 1980s, there has been an increase in the number of reported cases of pertussis in the US. In 2010, the CDC saw an increase in the number of reported cases among 7 to 10 years old. The CDC also observed an increase in the number of cases among teenagers. As a result, the rising incidences of the disease are further expected to boost the drug development for pertussis during the next few years.

 According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for pertussis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of pertussis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Bharat Biotech
• BIRMEX
• BlueWillow Biologics
• Cadila Healthcare
• LG Chem

Therapeutic assessment of the drug development for pertussis by route of administration

• Intramuscular
• Intranasal
• Subcutaneous
• Epicutaneous
• Intravenous

The intramuscular route of administration (ROA) involves the application of the drug directly into the drug, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development for pertussis by therapy

• Combination therapy
• Monotherapy

According to this pipeline analysis report, most of the molecules that are currently in the drug development for pertussis are being developed as combination therapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug molecules in the various development stages for pertussis?
• What are the companies that are currently involved in the development of drug molecules for pertussis?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.